ADVERTISEMENT

Bimekizumab appears highly effective in patients with axial spondyloarthritis

Medical News   |   25 January 2023
ADVERTISEMENT

Results from the BE MOBILE 1 and 2 clinical trials support the use of a dual IL-17A/F inhibitor, bimekizumab, as a new therapeutic option to treat axial spondyloarthritis (axSpA).

This chronic immune-mediated inflammatory disease mainly affects the joints that link the pelvis and the lower spine (sacroiliac), causing severe pain,...

          

Topic Challenges

left
right